BioSpace News Archive

Vaxcyte, Inc. announced that company management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on Wednesday, December 2, 2020 at 1:50pm ET.

Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in two upcoming virtual investor conferences:

Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Evercore ISI Annual HealthCONx Conference on December 3, 2020.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its underwritten public offering of 2,875,000 shares of its common stock, including 375,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares,

The Board of Directors of BD has declared a quarterly dividend of $0.83 per common share, an increase of 5.1% from the previous quarter.

Otsuka Pharmaceutical Development & Commercialization, Inc., and the Columbia University Mailman School of Public Health Enter Into a Global Pharmacovigilance Agreement PRINCETON, N.J. & NEW YORK--( BUSINESS WIRE )-- Otsuka Pharmaceutical Development & Commercialization, Inc., announced an agreement with research experts from the Columbia University Irving Center Vagelos College of Physicians and Surgeons and Mailman School of Public Health to

Twist Bioscience Corporation announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences:

bluebird bio, Inc. announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m. ET to review clinical data presented at the 62nd American Society of Hematology Annual Meeting and Exposition.

Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced a $50 million expansion of its sterile fill/finish manufacturing facilities located in Bloomington, Ind

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the following upcoming investor conference